John F. Crowley

John F. Crowley, Chairman and CEO of Amicus Therapeutics

John F. Crowley, Jerry

Amicus Therapeutics Chairman John F. Crowley leveraged his military background and personal family history with Pompe disease to guide the company through a strategic pivot that led to FDA-aligned pivotal trials for its candidate ATGAA. The therapy demonstrates significant clinical benefits in muscle strength and respiratory function, positioning the firm for a global launch to treat this underserved patient population. Building on lessons from the COVID-19 pandemic, Amicus aims to expand its portfolio of rare disease treatments by replicating the accelerated collaboration and regulatory agility established during that crisis.